PAYER POLICY CHANGES

C9093 Insurance Policy Changes

HCPCS C9093 is officially defined as "Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mg." HCPCS C9093 is referenced in 1 tracked payer policy change from Blue Cross and Blue Shield of Louisiana. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS C9093 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Watch C9093

Get one email when a payer policy names C9093, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

See every payer rule for C9093

Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for C9093 in one place.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.